more_reports

Francois Brisebois

Oppenheimer & Co.

Francois Brisbois is managing director and senior analyst at Oppenheimer & Co. Inc. covering biotechnology. Prior to joining Oppenheimer, he was a senior research analyst at Craig-Hallum Capital covering biotechnology and biopharmaceuticals. He previously worked at Laidlaw Capital Markets as a senior analyst covering biotechnology and specialty pharmaceuticals and started his Wall Street career at healthcare specialty firm Summer Street Research Partners. Brisebois holds a bachelor's degree in molecular biology from Colgate University and a Master of Science in pharmaceutical sciences from University of Montreal.

Recent Articles

Diagnostics Biotech Beats Revenue Estimates in Q3/23 10/11/2023

The Belgium-based company is well on its way to achieving, and possibly exceeding, full-year revenue guidance, noted an Oppenheimer report.

Biopharma Co. Adds CTO to Team 09/21/2023

This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.


Recent Quotes

"DRRX already exceeded enrollment in its Phase 1b NASH trial."

— Francois Brisebois, Craig-Hallum Capital (3/4/20)
more >



Due to permission requirements, not all quotes are shown.